When you're working with a compound like Tirzepatide, which is known for its nuanced effects, any deviation during reconstitution can lead to significant variability in your experimental outcomes
As a GIP receptor agonist, tirzepatide enhances insulin secretion in a glucose-dependent manner, reduces glucagon secretion, and may improve insulin sensitivity
Therefore, individuals who have great body composition will likely see fewer results, if any
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that activates: GLP-1 (glucagon-like peptide-1) receptor GIP (glucose-dependent insulinotropic polypeptide) receptor Glucagon (GCG) receptor This triple G mechanism targets multiple pathways for appetite control, insulin sensitivity, glucose regulation, and energy/fat metabolismpotentially offering greater effects than dual (GLP-1/GIP) or single agonists
On a GLP-1 medication with reduced food intake, most people fall well below this range without supplementation